INTELLIGENT BIO SOLUTIONS INC.
For the period ended Jun 30, 2025. Filed Aug 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Aug 15, 2025
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Convertible · Additional · Other · Non- · Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| preferred stock · Common stock · Treasury stock · paid-in · Accumulated · comprehensive · controlling · shareholders’ | ||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · income (loss) · interest · equity | ||||||||||||
| Balance, June 30, 2023 | - | $ | - | 194,200 | $1,942 | (116) | $(1) | $46,180,112 | $(41,807,573) | $(575,496) | $(111,986) | $3,686,998 |
| Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs | 5,728,723 | 57,287 | 186,018 | 1,860 | - | - | 3,727,017 | - | - | - | 3,786,164 | |
| Conversion of convertible preferred shares into common stock | (5,728,723) | (57,287) | 477,394 | 4,774 | - | - | 52,513 | - | - | - | - | |
| Conversion of holdback Series C Preferred Stock into common stock | - | - | 6,248 | 62 | - | - | 32,700 | - | - | - | 32,762 | |
| Issuance of common stock upon cashless exercise Series F warrants | - | - | 655,086 | 6,551 | - | - | (6,122) | - | - | - | 429 | |
| Reverse stock split rounding adjustment | - | - | 47,501 | 475 | - | - | (475) | - | - | - | - | |
| Issuance of common stock upon cash exercise of Series E warrants | - | - | 629,409 | 6,291 | - | - | 1,645,207 | - | - | - | 1,651,498 | |
| Issuance of restricted stock to vendors | - | - | 47,889 | 479 | - | - | 216,342 | - | - | - | 216,821 | |
| Issuance of common stock, Series I, H1 and H2 warrants, net of issuance costs | - | - | 675,183 | 6,752 | - | - | 9,110,829 | - | - | - | 9,117,581 | |
| Issuance of common stock upon exercise of Pre-funded warrants | - | - | 531,310 | 5,313 | - | - | - | - | - | - | 5,313 | |
| Stock awards issued to employees | - | - | 5,762 | 58 | - | - | 13,617 | - | - | - | 13,675 | |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | (137,118) | - | (137,118) | |
| Net loss | - | - | - | - | - | - | - | (10,156,759) | - | (34,173) | (10,190,932) | |
| Balance, June 30, 2024 | - | $ | - | 3,456,000 | $34,557 | (116) | $(1) | 60,971,740 | $(51,964,332) | $(712,614) | $(146,159) | $8,183,191 |
| Issuance of common stock upon exercise of warrants | - | - | 799,447 | 7,994 | - | - | (55) | - | - | - | 7,939 | |
| Stock awards issued to employees | - | - | 99,500 | 995 | - | - | 189,050 | - | - | - | 190,045 | |
| Issuance of restricted stock to vendors | - | - | 33,655 | 337 | - | - | 47,663 | - | - | - | 48,000 | |
| Issuance of common stock, net of issuance costs | - | - | 2,934,659 | 29,347 | - | - | 4,575,518 | - | - | - | 4,604,865 | |
| Foreign currency translation gain | - | - | - | - | - | - | - | - | 384,670 | - | 384,670 | |
| Net loss | - | - | - | - | - | - | - | (10,568,733) | - | (36,153) | (10,604,886) | |
| Balance, June 30, 2025 | - | $ | - | 7,323,261 | $73,230 | (116) | $(1) | $65,783,916 | $(62,533,065) | $(327,944) | $(182,312) | $2,813,824 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.